Abstract library

77 results for "Eng Eibak".
#2977 Predicting Survival in Patients with a Neuroendocrine Tumor of the Small Intestine (SI-NET)
Introduction: SI-NET comprise the largest group of neuroendocrine tumors. Because of their heterogeneity, predicting survival has proven challenging. A nomogram (NG) to assess SI-NET disease specific survival (DSS) has been developed in 2010 by Modlin, et al. based on analysis of retrospective data from the Surveillance, Epidemiology and End Results (SEER) database.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Sonja Levy
Keywords: SI-NET, Nomogram, Survival
#2803 Chromogranin A as a Tumoral Marker for Neuroendocrine Tumors in Chilean Patients: A Case-Control Study
Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous, serum chromogranin A (CgA) has a 60-100% of sensitivity and 68-100% of specificity with a cutoff value of 108 ng/mL as a marker for diagnosis of NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Matias Munoz Medel
#17 Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls
Introduction: The diagnosis of Zollinger-Ellison syndrome is suspected in patients with symptoms of gastric acid hypersecretion, i.e., peptic ulcer disease, malabsorption or diarrhea, or with elevated fasting serum gastrin levels. However, symptoms can be masked by the use of proton pump inhibitors and fasting serum gastrin values are not always conclusive. Therefore, the secretin stimulation test is advocated as the principal diagnostic tool to identify the Zollinger-Ellison syndrome.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Patricia Kuiper
#86 Structure of complications in acromegalic patients at a single institute
Introduction: Acromegaly leads to reduced life expectancy, with an increase in the mortality rate. From several retrospective cohort studies, the predominant outcome is serum growth hormone (GH) concentration. Other factors associated with increased mortality include duration of symptoms prior to diagnosis, duration of disease, older age at diagnosis and the presence of cardiovascular disease, diabetes mellitus (DM) and hypertension at diagnosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: OKH OKSANA OLEGOVNA KHYZHNYAK
#967 Correlation Between Genomic Imbalances, Cell Proliferation and Tumor Size in Sporadic Pancreatic Neuroendocrine Tumors
Introduction: The pathogenesis of sporadic pancreatic neuroendocrine tumors (pNET) is poorly understood.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: MD Sven Petter Haugvik
#1078 Somatostatin Responsive ACTH and Precursor Excess in a Midgut Mesentery NET
Introduction: ACTH production from a midgut mesentery NET is extremely rare (1). A 62y old woman presented with hypokalaemia (2mmol/L) and hyperpigmentation, 11y after surgery of a pT3N1Mx non-functional G1 NET with SRS positive, non-resectable but stable, residual mass encasing mesenteric vessels. Serum cortisol (3261 nmol/L), ACTH (796 ng/L), CgA (530 pmol/L) and urine total cortisol metabolites (33920 µg/24h) including 14 sub-products indicated change of biological behaviour into a functioning NET. Pituitary or pulmonary sources were excluded
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr., Ass Prof. Martin O. Weickert
#1197 The Neuron-Specific Enolase Assessment in Patients with Neuroendocrine Tumors with or without Carcinoid Syndrome
Introduction: NeuroEndocrine Tumors (NETs) comprises a wide area of clinical presentations and neuroendocrine markers.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Biomarkers
Presenting Author: MD Mara Carsote
#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience
Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Lih Ming Loh
#1466 Delays in Diagnosing Neuroendocrine Tumours by Secondary Care Specialities
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to be a diagnostic challenge, many patients presenting with metastatic disease to a number of specialities in secondary care
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Benny A, Ng S, Reid K, Williams M, ...
#1470 Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours
Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
Authors: Williams M, Reid K, Ng S, Benny A, ...